Aspirin-exacerbated respiratory diseases: pathogenesis and treatment strategies

doi:10.19982/j.issn.1000-6621.20240216

Abstract

Abstract:

Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome characterized by chronic rhinosinusitis with nasal polyps, asthma, and hypersensitivity to cyclooxygenase-1 (COX-1) inhibitors. Although the precise pathogenesis of AERD remains unclear, it is widely acknowledged that aberrant metabolism of arachidonic acid plays a central role in the development of this condition. Owing to the incomplete understanding of AERD, many clinicians struggle to establish an accurate diagnosis, which significantly compromises treatment outcomes. Current therapeutic approaches primarily include symptomatic pharmacological management, surgical interventions, aspirin desensitization, and the use of biologic agents. The author aims to provide a comprehensive overview of the pathogenesis and therapeutic strategies for AERD.

Key words: Aspirin, Aspirin-exacerbated respiratory diseases, Therapeutic uses, Program evaluation

CLC Number:

Ming Wenhua, Ma Tingting, Wang Hongtian, Wang Xueyan. Aspirin-exacerbated respiratory diseases: pathogenesis and treatment strategies[J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1400-1405. doi: 10.19982/j.issn.1000-6621.20240216

References 44

[1]	Rajan JP, Wineinger NE, Stevenson DD, et al. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol, 2015, 135(3): 676-681. e1. doi:10.1016/j.jaci.2014.08.020. pmid: 25282015
[2]	Dominas C, Gadkaree S, Maxfield AZ, et al. Aspirin-exacerbated respiratory disease: A review. Laryngoscope Investig Otolaryngol, 2020, 5(3): 360-367. doi:10.1002/lio2.387. pmid: 32596477
[3]	Hahn J, Appel H, Scheithauer MO, et al. Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid. Am J Rhinol Allergy, 2020, 34(4): 554-563. doi:10.1177/1945892420912362. pmid: 32208749
[4]	Laidlaw TM, Levy JM. NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets. Curr Allergy Asthma Rep, 2020, 20(4): 10. doi:10.1007/s11882-020-00905-9.
[5]	Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol, 2021, 11(3): 213-739. doi:10.1002/alr.22741.
[6]	Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis, 1991, 144(4): 957-958. doi:10.1164/ajrccm/144.4.957.
[7]	San Nicoló M, Habermann N, Havel M. AERD Associated Nasal Polyposis: Efficacy of Postoperative Antileukotriene Therapy in Comparison with Aspirin Desensitization. A Retrospective Study. Int Arch Allergy Immunol, 2020, 181(10): 790-798. doi:10.1159/000508708.
[8]	Li KL, Lee AY, Abuzeid WM. Aspirin Exacerbated Respiratory Disease: Epidemiology, Pathophysiology, and Management. Med Sci (Basel), 2019, 7(3): 45. doi:10.3390/medsci7030045.
[9]	Laidlaw TM, Gakpo DH, Bensko JC, et al. Leukotriene-Associated Rash in Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract, 2020, 8(9): 3170-3171. doi:10.1016/j.jaip.2020.06.061. pmid: 32739465
[10]	Makary CA, Holmes T, Unsal A, et al. Long-term role of zileuton in the treatment of chronic rhinosinusitis in aspirin exacerbated respiratory disease. Am J Otolaryngol, 2022, 43(1): 103227. doi:10.1016/j.amjoto.2021.103227.
[11]	Nasser SM, Bell GS, Foster S, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax, 1994, 49(8): 749-756. doi:10.1136/thx.49.8.749. pmid: 8091318
[12]	Sansing-Foster V, Haug N, Mosholder A, et al. Risk of Psychiatric Adverse Events Among Montelukast Users. J Allergy Clin Immunol Pract, 2021, 9(1): 385-393. e12. doi:10.1016/j.jaip.2020.07.052. pmid: 32795564
[13]	Cetkovská P, Pizinger K. Childhood pemphigus associated with montelukast administration. Clin Exp Dermatol, 2003, 28(3): 328-329. doi:10.1046/j.1365-2230.2003.01266.x.
[14]	Di Salvo E, Patella V, Casciaro M, et al. The leukotriene receptor antagonist Montelukast can induce adverse skin reactions in asthmatic patients. Pulm Pharmacol Ther, 2020, 60: 101875. doi:10.1016/j.pupt.2019.101875.
[15]	Incecik F, Onlen Y, Sangun O, et al. Probable montelukast-induced hepatotoxicity in a pediatric patient: case report. Ann Saudi Med, 2007, 27(6): 462-463. doi:10.5144/0256-4947.2007.462. pmid: 18059126
[16]	Wooltorton E. Asthma drug zafirlukast (Accolate): serious hepatic events. CMAJ, 2004, 170(11): 1668. doi:10.1503/cmaj.1040720.
[17]	Watkins PB, Dube LM, Walton-Bowen K, et al. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug Saf, 2007, 30(9): 805-815. doi:10.2165/00002018-200730090-00006.
[18]	Mendelsohn D, Jeremic G, Wright ED, et al. Revision rates after endoscopic sinus surgery: a recurrence analysis. Ann Otol Rhinol Laryngol, 2011, 120(3): 162-166. doi:10.1177/000348941112000304.
[19]	Sweis AM, Locke TB, Ig-Izevbekhai KI, et al. Effectiveness of endoscopic sinus surgery and aspirin therapy in the management of aspirin-exacerbated respiratory disease. Allergy Asthma Proc, 2021, 42(2): 136-141. doi:10.2500/aap.2021.42.210002. pmid: 33685558
[20]	Bosso JV. Aspirin desensitization for aspirin-exacerbated respiratory disease in the era of biologics: Clinical perspective. Int Forum Allergy Rhinol, 2021, 11(4): 822-823. doi:10.1002/alr.22709.
[21]	Walters KM, Waldram JD, Woessner KM, et al. Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease. Am J Rhinol Allergy, 2018, 32(4): 280-286. doi:10.1177/1945892418770260. pmid: 29682983
[22]	Stevens WW, Jerschow E, Baptist AP, et al. The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol, 2021, 147(3): 827-844. doi:10.1016/j.jaci.2020.10.043.
[23]	Taniguchi M, Mitsui C, Hayashi H, et al. Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD. Allergol Int, 2019, 68(3): 289-295. doi:10.1016/j.alit.2019.05.001. pmid: 31235242
[24]	Locke TB, Sweis AM, Gleeson PK, et al. Age as a factor in treatment of aspirin-exacerbated respiratory disease: relationship to required aspirin maintenance dose after desensitization. Int Forum Allergy Rhinol, 2020, 10(10): 1180-1181. doi:10.1002/alr.22665.
[25]	D’Souza GE, Nwagu U, Barton B, et al. Outcomes of aspirin exacerbated respiratory disease patients treated with aspirin desensitization and biologics. Int Forum Allergy Rhinol, 2022, 12(3): 306-309. doi:10.1002/alr.22900.
[26]	Bavaro N, Gakpo D, Mittal A, et al. Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5Rα in a real-world setting. J Allergy Clin Immunol Pract, 2021, 9(7): 2910-2912. e1. doi:10.1016/j.jaip.2021.02.020. pmid: 33631410
[27]	Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med, 2018, 378(26): 2486-2496. doi:10.1056/NEJMoa1804092.
[28]	Oykhman P, Paramo FA, Bousquet J, et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. J Allergy Clin Immunol, 2022, 149(4): 1286-1295. doi:10.1016/j.jaci.2021.09.009.
[29]	Mustafa SS, Vadamalai K, Scott B, et al. Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease. Am J Rhinol Allergy, 2021, 35(3): 399-407. doi:10.1177/1945892420961969.
[30]	Patel P, Bensko JC, Bhattacharyya N, et al. Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol, 2022, 128(3): 326-328. doi:10.1016/j.anai.2021.11.020.
[31]	Buchheit KM, Laidlaw TM, Levy JM. Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol, 2021, 148(2): 348-350. doi:10.1016/j.jaci.2021.06.019. pmid: 34174296
[32]	Tuttle KL, Buchheit KM, Laidlaw TM, et al. A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract, 2018, 6(3): 1045-1047. doi:10.1016/j.jaip.2018.01.038. pmid: 29501519
[33]	Wangberg H, Spierling Bagsic SR, Osuna L, et al. Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract, 2022, 10(2): 478-484. e3. doi:10.1016/j.jaip.2021.09.030.
[34]	Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med, 2021, 9(10): 1141-1153. doi:10.1016/S2213-2600(21)00097-7. pmid: 33872587
[35]	Buchheit KM, Lewis E, Gakpo D, et al. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol, 2021, 148(2): 574-584. doi:10.1016/j.jaci.2021.05.043. pmid: 34144111
[36]	Workman AD, Bleier BS. Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: A review of preliminary data, efficacy, and cost. World J Otorhinolaryngol Head Neck Surg, 2020, 6(4): 230-234. doi:10.1016/j.wjorl.2020.06.002.
[37]	Hayashi H, Mitsui C, Nakatani E, et al. Omalizumab reduces cysteinyl leukotriene and 9alpha,11beta-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol, 2016, 137(5): 1585-1587. e4. doi:10.1016/j.jaci.2015.09.034.
[38]	Hayashi H, Fukutomi Y, Mitsui C, et al. Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial. Am J Respir Crit Care Med, 2020, 201(12): 1488-1498. doi:10.1164/rccm.201906-1215OC.
[39]	Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol, 2020, 146(3): 595-605. doi:10.1016/j.jaci.2020.05.032. pmid: 32524991
[40]	Quint T, Dahm V, Ramazanova D, et al. Omalizumab-Induced Aspirin Tolerance in Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease Patients Is Independent of Atopic Sensitization. J Allergy Clin Immunol Pract, 2022, 10(2): 506-516. e6. doi:10.1016/j.jaip.2021.09.050.
[41]	Schneider TR, Johns CB, Palumbo ML, et al. Dietary Fatty Acid Modification for the Treatment of Aspirin-Exacerbated Respiratory Disease: A Prospective Pilot Trial. J Allergy Clin Immunol Pract, 2018, 6(3): 825-831. doi:10.1016/j.jaip.2017.10.011. pmid: 29133219
[42]	Laidlaw TM, Cahill KN, Cardet JC, et al. A trial of type 12 purinergic (P2Y(12)) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol, 2019, 143(1): 316-324. e7. doi:10.1016/j.jaci.2018.06.001. pmid: 29890239
[43]	Corren J, Parnes JR, Wang L, et al. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med, 2017, 377(10): 936-946. doi:10.1056/NEJMoa1704064.
[44]	Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med, 2021, 384(19): 1800-1809. doi:10.1056/NEJMoa2034975.